FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. ("Cytek Biosciences” or "Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.

Total revenue for the second quarter of 2025 was $45.6 million, representing a 2% decrease compared to the second quarter of 2024 Expanded to a total installed base of 3,295 Cytek instruments, adding ...

FREMONT, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Continuing its commitment to advancing cell analysis, Cytek Biosciences, Inc. (Nasdaq: CTKB) is showcasing its patented Full Spectrum Profiling™ ...

Cytek will present and participate in a Q&A session at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on January 16, 2025, at 8:15 a.m. Pacific time. Interested parties may ...

(MENAFN- GlobeNewsWire - Nasdaq) FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min CyTek Corp., a Kansas City-based ...